Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.78 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.65 |
| ▸ | CXCL12 | P48061 | 9/20 | 0.65 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.64 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25219790 | 0.89 | MAPT (0.67) | KDRFGFR1CXCL12CXCR4ACHE | |
| SCHEMBL19782818 | 0.89 | MAPT (0.67) | KDRFGFR1CXCL12CXCR4ACHE | |
| SCHEMBL12677857 | 0.84 | CXCL12 (0.89) | CXCL12CXCR4 | |
| SCHEMBL25193952 | 0.84 | CXCL12 (0.89) | CXCL12CXCR4 | |
| SCHEMBL30384490 | 0.84 | CXCL12 (0.89) | CXCL12CXCR4 | |
| SCHEMBL25280277 | 0.83 | CXCL12 (0.66) | KDRFGFR1CXCL12CXCR4ACHE | |
| SCHEMBL25203022 | 0.83 | CXCL12 (0.66) | KDRFGFR1CXCL12CXCR4ACHE | |
| SCHEMBL30383603 | 0.83 | CXCL12 (0.66) | KDRFGFR1CXCL12CXCR4ACHE | |
| SCHEMBL21802480 | 0.81 | CTSL (0.68) | KDRABCB1MAOB | |
| SCHEMBL29535965 | 0.81 | CTSL (0.68) | KDRABCB1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046657-B2 | Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-06-29 | — | — | US | disclosed |
| US-20200181093-A1 | Pyrimidinone Derivatives and Uses Thereof to Neutralize the Biological Activity of Chemokines | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2020-06-11 | — | — | US | disclosed |
| WO-2018011376-A1 | PYRIMIDINONE DERIVATIVES AND USES THEREOF TO NEUTRALIZE THE BIOLOGICAL ACTIVITY OF CHEMOKINES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (FR) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181093-A1 | Pyrimidinone Derivatives and Uses Thereof to Neutralize the Biological Activity of Chemokines | CCL5, CXCR3, CXCL10 | KDR 3499/4885FGFR1 2402/4885CXCL12 18/4885 |
| US-11046657-B2 | Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines | CCL5, CXCR3, CXCL10 | KDR 3499/4885FGFR1 2402/4885CXCL12 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.